DRMA Research | Milton Maxwell

DRMA

Dermata Therapeutics, Inc.

2.3200

-0.1600-6.45%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

2.38M

P/E (TTM)

0.15

Basic EPS (TTM)

15.24

Dividend Yield

Recent Filings

8-K

Board member resigns

2/25/26Feb 25, 2026

Dermata Therapeutics' board member Mary Fisher resigned effective March 31, 2026, after notifying the company on February 23, due to her employer's acquisition barring outside board service. No disagreements with management or operations. Board shrinks from eight to seven.

8-K

Auditor change disclosed

2/3/26Feb 3, 2026

Dermata Therapeutics dismissed Baker Tilly as its auditor on January 30, 2026, effective January 31, after clean reports for 2023-2024 save going concern warnings. No disagreements or reportable events occurred. The Audit Committee swiftly appointed prior firm CBIZ CPAs on February 2. Smooth switch.

8-K

ATM offering expanded $705K

1/27/26Jan 27, 2026

Dermata Therapeutics upped its at-the-market offering by $705,000 via prospectus supplement on January 27, 2026, under the June 2024 Sales Agreement with H.C. Wainwright. This adds to $3,454,390 previously sold. Fresh legal opinion backs the new shares. Funding taps Nasdaq liquidity.

8-K

Dermata raises $4.1M privately

12/29/25Dec 29, 2025

Dermata Therapeutics closed a $4.1M private placement on December 23, 2025, issuing 1.5M shares (or pre-funded warrants), Series C/D warrants for 2M shares at $2.04 exercise price—net ~$3.7M after fees. Insiders chipped in $1.5M; proceeds fuel OTC acne kit launch and M&A. Warrants need stockholder approval. Dilution looms large.

8-K

Terminates Villani license

11/18/25Nov 18, 2025

Dermata Therapeutics terminated its 2017 license agreement with Villani, Inc. without cause on November 17, 2025, effective 90 days after notice amid a pivot to OTC skincare and XYNGARI™ IND withdrawal. This ends up to $40.5M in milestones and royalties on sponge-based skin treatments. No further payments due. Obligations vanish.

About

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

CEO

Mr. Gerald T. Proehl

IPO

8/13/2021

Website

https://www.dermatarx.com

Employees

Sector

Healthcare

Industry

Biotechnology